Because median serum TGF-β1 levels in HCC patients are approximately 13.7 ng/mL35, it is relevant that TGF-β1 secreted from tumor microenvironment can induce xCT repression and enhance GPX4 inhibitor-mediated cell death in these HCC cells. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.